Frequently asked · the blend
BPC-157 TB-500: frequently asked questions about the Wolverine blend
Direct answers from the published record — what is established for each constituent, and where the combination's data reads blank.
Identity and rationale
What is the Wolverine peptide blend?
A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair stack. It is not a single chemical entity and not an approved product, and the name carries none of its pop-culture sense [1][3].
What is BPC-157 and TB-500?
BPC-157 is a 15-amino-acid pentadecapeptide derived from a human gastric-juice protein; TB-500 is the synthetic Ac-LKKTETQ fragment of Thymosin Beta-4 [1][3]. The blend pairs them as a tissue-repair stack with two distinct mechanisms — different sequences, sizes, and targets.
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid gastric-derived pentadecapeptide acting as a cytoprotective and angiogenic signal; TB-500 is a 7-amino-acid actin-binding fragment of Thymosin Beta-4 acting as a cytoskeletal-migration signal. Different sequences, sizes (~1419 Da vs ~889 Da), and mechanisms [3][4].
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The rationale is complementary mechanisms: BPC-157's angiogenic and cytoprotective signal plus TB-500's cytoskeletal-migration signal. This is a theoretical extrapolation from each peptide's characterized mechanism, not a finding from a controlled combination study [2][3][4].
Mechanism
How does TB-500 work (actin / Thymosin Beta-4)?
TB-500 is the Ac-LKKTETQ fragment of Thymosin Beta-4; the LKKTETQ motif binds monomeric G-actin in a 1:1 complex, regulating the cytoskeletal dynamics that drive cell migration [3]. Its chemical identity was fixed by synthesis as a doping-control reference [9].
How does BPC-157 work compared to TB-500?
BPC-157 supplies a cytoprotective and angiogenic signal through VEGFR2-Akt-eNOS, while TB-500 supplies an actin-sequestration and cell-migration signal through G-actin binding [2][3]. The two are described as complementary but largely non-overlapping pathways.
Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?
In preclinical models both do, by distinct routes: BPC-157 via VEGFR2-Akt-eNOS [2], and TB-500 / Thymosin Beta-4 via endothelial migration [4]. That shared vascular thread is cited in the blend rationale, though the two reach it through different machinery.
Efficacy and evidence
What is the BPC-157 and TB-500 blend used for in research?
In animal models, the constituents are studied for tendon, ligament, and muscle repair, angiogenesis, and wound healing [1][4][6]. No human efficacy data exist for the combination — every benefit traces to single-compound, mostly rodent studies.
Does the BPC-157 TB-500 blend help tendon and ligament injuries?
Animal studies of the individual peptides report improved tendon and ligament healing — BPC-157 in transected rat Achilles tendon [1] and rat medial collateral ligament [6] — but no combination study and no human efficacy data exist.
Does BPC-157 and TB-500 help muscle tears and recovery?
Preclinical rodent studies report muscle-repair effects for each peptide — BPC-157 after surgical quadriceps detachment [13], and Thymosin Beta-4 mobilizing cells to injured tissue [4] — but the combination's effect in humans is unproven.
Does the BPC-157 TB-500 blend help wound healing?
Animal models report wound-healing effects for the individual peptides — for example, Thymosin Beta-4 promoting re-epithelialization and angiogenesis [4] — but no combination or human data exist. The blend leans on single-compound evidence.
How long does it take BPC-157 and TB-500 to work for an injury?
No human timeline data exist for the blend. Animal studies report healing improvements over days to weeks for the individual peptides [1][6], but these are species- and model-specific and do not translate to a human schedule.
Is there any study showing BPC-157 and TB-500 work better together (synergy)?
No. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together; the 2025 HSS Journal BPC-157 systematic review makes no mention of TB-500 or combination use [10].
Are there human clinical trials on the BPC-157 + TB-500 combination?
No. There are no controlled clinical trials of the combination. Human data exist only for the individual constituents and are themselves thin — and for TB-500 are on full-length Thymosin Beta-4, not the 7-mer [4][9][10].
Dosing context
How do you cycle BPC-157 and TB-500?
There is no validated cycling protocol. Fixed-ratio vials (such as 10 mg + 10 mg) and "loading" schedules circulating online have no basis in controlled human trials, and a rat study found Thymosin Beta-4 dosing non-monotonic — higher was not better.
How much BPC-157 and TB-500 should be used per week?
There is no validated weekly dose for the blend. Animal doses are expressed per body weight — BPC-157 at roughly 10 microg/kg [1], Thymosin Beta-4 across a wide mg/kg range — which does not convert to a human regimen.
What is the half-life of BPC-157 and TB-500?
BPC-157's elimination half-life was reported under 30 minutes in animal PK studies. No validated human half-life exists for either constituent at research-use doses, and none for the blend; no specific half-life is established for the TB-500 heptapeptide.
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both constituents are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated. Product identity and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed, which compounds the TB-500-vs-full-length-Thymosin-Beta-4 identity caveat [4][9].
How often should you inject BPC-157 and TB-500?
There is no validated dosing schedule for the blend. Community "loading then maintenance" protocols have no controlled-trial basis and should not be presented as validated dosing. Injection frequency for the combination is undefined in the peer-reviewed literature.
Safety
What are the side effects of BPC-157 and TB-500?
The combination's safety is unproven. A key theoretical concern is the pro-angiogenic and pro-migratory tumor signal associated with Thymosin Beta-4 [4]; BPC-157's long-term human safety is unknown, and a 2025 systematic review found no clinical safety data for it [10].
Does TB-500 cause cancer or promote tumor growth?
Thymosin Beta-4 is implicated in tumor metastasis and angiogenesis; the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [4]. This is a noted safety consideration, not an established human risk for the fragment.
Regulatory
Are BPC-157 and TB-500 FDA approved or banned by WADA?
Neither is FDA-approved for human use [14], and both are prohibited by WADA — BPC-157 under the S0 non-approved-substances category, and TB-500 / thymosin beta-4 under prohibited peptide and growth-factor categories.
Is Wolverine legal?
The blend has no approved indication, and neither constituent is FDA-approved. BPC-157 and the TB-500 / thymosin beta-4 fragment are each FDA 503A Category 2 bulk substances as of the September 29, 2023 update — see Wolverine legal status and 503A compounding access for the full picture [14].
Can you get BPC-157 from a compounding pharmacy?
BPC-157 is currently an FDA 503A Category 2 bulk substance, identified as potentially presenting significant safety risks and not within FDA's enforcement-discretion policy for compounding [14]. Eligibility is what FDA is still evaluating, with a PCAC discussion scheduled for July 2026 [16].
What is the FDA 503A status of Wolverine?
The blend has no approved indication; its constituents BPC-157 and the TB-500 / thymosin beta-4 fragment are each FDA 503A Category 2 bulk substances effective September 29, 2023 [14], and both are on the scheduled July 23-24, 2026 PCAC agenda as substances being considered for the 503A Bulks List [16].